|
Safety Information
Prograf® (tacrolimus capsules and injection) is approved for the prevention of rejection in patients who have received a liver or kidney transplant. Only physicians and facilities specializing in transplantation should manage patients taking Prograf. Anti-rejection medications may result in an increased possibility of developing an infection or lymphoma, a type of cancer.
In clinical studies, up to 20% of patients taking Prograf developed insulin dependent diabetes after transplant, but in some patients, after two years, insulin was no longer required. Black and Hispanic kidney transplant patients were at an increased risk.
Prograf has been associated with toxicity to the kidneys and nervous system. Common side effects are tremor, headache, high blood pressure, diarrhea, nausea and changes in kidney function.
Prograf should not be used in patients allergic to tacrolimus. Prograf injection should not be used in patients allergic to castor oil.
Prograf Prescribing Information 
Prograf Patient Information
Prograf Safety Information
|
PRINT THIS PAGE
